Astellas Pharma Overview
Valuation check: ALPMY's ROE is 15.76%, below the Healthcare sector average of 21.67%.
Get informed when a big investor buys or sells
+ Follow15.76%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Astellas Pharma posts a ROE of 15.76%. That is below the Healthcare sector average of 21.67%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 21.67% is typical. Astellas Pharma's 15.76% is lower that level. That is roughly 27.3% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Astellas Pharma's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 15.76%; use YoY and peer views to separate noise from signal.
Context for ALPMY's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 21.67%), and (3) consistency with growth and profitability. This page covers the first two; Astellas Pharma's other metric pages and overview cover the third.
Judging Astellas Pharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 15.76% here, then scan peer and history charts to see if the gap is persistent.
